Vardenafil orodispersible tablet

Drugs

Volumn 72, Issue 1, 2012, Pages 87-98

  Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Dis Drug Profiles; Erectile dysfunction; Vardenafil

Indexed keywords

ALCOHOL; ATAZANAVIR; CLARITHROMYCIN; CYCLIC GMP; CYTOCHROME P450 2C; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOXAZOSIN; ERYTHROMYCIN; GLYCERYL TRINITRATE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NITRATE; PLACEBO; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL; WARFARIN;

ACUTE CORONARY SYNDROME; AGE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FATIGUE; FILM COATED TABLET; GASTROINTESTINAL HEMORRHAGE; GRAPEFRUIT JUICE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IN VITRO STUDY; INTERNATIONAL INDEX OF ERECTILE FUNCTION; ISCHEMIC OPTIC NEUROPATHY; KIDNEY FAILURE; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MOUTH DISEASE; NOSE CONGESTION; ORODISPERSIBLE TABLET; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINITIS PIGMENTOSA; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SUPRAVENTRICULAR PREMATURE BEAT; SYNCOPE; TABLET; THORAX PAIN; TREATMENT DURATION; VASODILATATION; XEROSTOMIA;

ADMINISTRATION, ORAL; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONES; TABLETS; TREATMENT OUTCOME; TRIAZINES;

EID: 84055190600     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208270-000000000-00000     Document Type: Article

References (37)

1. Qaseem A, Snow V, Denberg DT, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Ann Int Med 2009 Nov 3; 151 (9): 639-49
2. Rosen RC, Fisher WA, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20 (5): 607-17
3. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology. Eur Urol 2010 May; 57 (5): 804-14
4. Keating GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. Drugs 2003; 63 (23): 2673-703 (Pubitemid 37491567)
5. Giuliano F, Donatucci C, Montorsi F, et al. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int Suppl 2005; 95 (1): 110-6 (Pubitemid 350027199)
6. Schneider T, Gleibner J, Merfort F, et al. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebocontrolled trial. J Sex Med 2011 Oct; 8 (10): 2904-11
7. Ishii N, Nagao K, Fujikawa K, et al. Vardenafil 20-mg demonstrated superior efficacy to 10 mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006 Aug; 13 (8): 1066-72 (Pubitemid 44125678)
8. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 Mar; 26 (3): 777-83 (Pubitemid 36929343)
9. Shabsigh R, Duval S, Shah M, et al. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin 2007 Oct; 23 (10): 2453-60 (Pubitemid 350033447)
10. van Ahlen H, Wahle K, Kupper W, et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005 Nov; 2 (6): 856-64 (Pubitemid 41727399)
11. Miner M, Gilderman L, Bailen J, et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008 Jun; 5 (6): 1455-67 (Pubitemid 351803112)
12. Miner MM, Barnes A, Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010 May; 7 (5): 1937-47
13. Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006 Jan 24; 66 (2): 210-6
14. Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury. Spine 2008 Apr 1; 33 (7): 709-15 (Pubitemid 351489406)
15. Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003 Oct; 170 (4 Pt 1): 1278-83 (Pubitemid 37108132)
16. Nehra A, Grantmyre J, Nadel A, et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005 Jun; 173 (6): 2067-71 (Pubitemid 40675245)
17. Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008 Oct; 54 (4): 924-31
18. Candy B, Jones L, Williams R, et al. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review. BJU Int 2008 Aug; 102 (4): 426-31 (Pubitemid 352032841)
19. Zumbe J, Porst H, Sommer F, et al. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 2008 Jul; 54 (1): 204-10
20. Heinig R, Weimann B, Dietrich H, et al. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin Drug Invest 2011; 31 (1): 27-41
21. European Medicines Agency. Levitra 10mg orodispersible tablets: summary of product characteristics [online]. Available from URL: http://www. ema. europa. eu/docs/ en-GB/document-library/EPAR-Product-Informa tion/human/000475/WC500039992. pdf [Accessed 2011 Sep 6]
22. Bayer Healthcare Pharmaceuticals Inc. Staxyn (vardenafil hydrochloride) orally disintegrating tablets: prescribing information [online]. Available from URL: http://www. accessdata. fda. gov/drugsatfda-docs/label/2010/200179lbl. pdf [Accessed 2011 Aug 18]
23. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase- 5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004 Nov 9; 110: 3149-55 (Pubitemid 39492012)
24. Schwarz BG, Kloner RA. Drug interactions with phosphodiesterase- 5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation 2010 Jul 6; 122: 88-95
25. Thadani U, SmithW, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002 Dec 4; 40 (11): 2006-12 (Pubitemid 35425369)
26. FossaAA, LangdonG, Couderc J-P, et al. The use of beat-tobeat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil. Clin Pharmacol Ther 2011 Sep; 90 (3): 449-54
27. Taner P, Basar MM, Unal B, et al. Effects of vardenafil on intraocular pressure and orbital hemodynamics. J Ocul Pharmacol Ther 2007 Jun; 23 (3): 275-9 (Pubitemid 46986608)
28. Jarvi K, Dula E, Drehobl M, et al. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol 2008 Mar; 179 (3): 1060-5
29. Ng CF, Wong A, Cheng CW, et al. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. J Urol 2008 Sep; 180 (3): 1042-6
30. European Medicines Agency. Levitra 5mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR-Product-Information/human/ 000475/WC500039992. pdf [Accessed 2011 Oct 17]
31. Sperling H, Debruyne F, Boermans A, et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010 Apr; 7 (4 Pt 1): 1497-507
32. GittelmanM,McMahon CG,Rodriguez-Rivera JA, et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int JClin Pract 2010Apr; 64 (5): 594-603
33. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 Jun; 49 (6): 822-30 (Pubitemid 27246947)
34. Sperling H, Gittelman M, Norenberg C, et al. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J Sex Med 2011 Jan; 8 (1): 261-71
35. Debruyne FMJ, Gittelman M, Sperling H, et al. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med 2011 Oct; 8 (10): 2912-23
36. Rosen RC, Cappelleri JC, Gendrano N III. The International Index of Erectile Function (IIEF): a state-of-thescience review. Int J Impot Res 2002 Aug; 14 (4): 226-44 (Pubitemid 34947726)
37. Hazell L, Cornelius V, Wilton L, et al. Mortality due to ischaemic heart disease in 15,659 patients prescribed vardenafil in general practice in England (2005): results from a prescription-event monitoring (PEM) study [abstract no. 387]. Pharmacoepidemiol Drug Saf 2009; 18 Suppl. : S168-9